Journal article

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, D Schadendorf, R Dummer, M Smylie, P Rutkowski, PF Ferrucci, A Hill, J Wagstaff, MS Carlino, JB Haanen, M Maio, I Marquez-Rodas, GA McArthur, PA Ascierto, GV Long Show all

NEW ENGLAND JOURNAL OF MEDICINE | MASSACHUSETTS MEDICAL SOC | Published : 2015

Abstract

BACKGROUND: Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab plus ipilimumab was compared with ipilimumab alone in patients with metastatic melanoma. METHODS: We assigned, in a 1:1:1 ratio, 945 previously untreated patients with unresectable stage III or IV melanoma to nivolumab alone, nivolumab plus ipilimumab, or ipilimumab alone. Progression-free survival and overall survival were coprimary end points. Results regarding progression-free su..

View full abstract

University of Melbourne Researchers